작년, Organon & Co의 가장 좋은 성과를 낸 부문인 Women’s Health는 1.75B달러의 수익을 올렸습니다. Europe and Canada이 가장 큰 기여를 하여, 작년에 1.62B달러에 달했습니다. 최근 분기에 2026-06-30를 기준으로 Organon & Co이 Women’s Health 부문에서 419.00M달러의 수익을 보고했습니다. Europe and Canada가 가장 높은 수익 기여를 하여 432.00M달러를 기록했습니다.

사업별

수익

비율

연간

연간

분기별

Women’s Health

Cardiovascular

Non-Opioid Pain, Bone and Dermatology

Respiratory

Other

Biosimilars

Other Organon Products segment

Supply sales to Merck affiliates

Other Merck Retained Products segment

Keytruda

Januvia/Janumet

Simponi

Zostavax

Gardasi/Gardasil

Varivax

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

Women’s Health

1.75B(28.19%)

1.78B(27.75%)

1.70B(27.18%)

1.67B(27.10%)

1.61B(25.57%)

1.55B(23.79%)

2.26B(29.09%)

2.10B(21.52%)

1.99B(18.96%)

Cardiovascular

1.14B(18.26%)

1.32B(20.66%)

1.46B(23.31%)

1.50B(24.25%)

1.62B(25.63%)

1.87B(28.67%)

2.07B(26.66%)

2.33B(23.88%)

3.01B(28.70%)

Non-Opioid Pain, Bone and Dermatology

987.00M(15.88%)

867.00M(13.54%)

782.00M(12.49%)

788.00M(12.76%)

830.00M(13.17%)

834.00M(12.77%)

884.00M(11.37%)

737.00M(7.54%)

810.00M(7.71%)

Respiratory

842.00M(13.55%)

1.02B(15.90%)

1.06B(16.99%)

1.04B(16.80%)

1.01B(16.02%)

1.15B(17.62%)

1.47B(18.90%)

1.58B(16.15%)

1.72B(16.41%)

Other

809.00M(13.01%)

756.00M(11.81%)

662.00M(10.57%)

698.00M(11.31%)

611.00M(9.69%)

683.00M(10.46%)

734.00M(9.44%)

550.00M(5.63%)

573.00M(5.46%)

Biosimilars

691.00M(11.12%)

662.00M(10.34%)

593.00M(9.47%)

481.00M(7.79%)

423.00M(6.71%)

331.00M(5.07%)

251.00M(3.23%)

63.00M(0.64%)

5.00M(0.05%)

Other Organon Products segment

--(--)

202.00M(3.20%)

106.00M(1.62%)

103.00M(1.32%)

924.00M(9.45%)

1.08B(10.32%)

Supply sales to Merck affiliates

--(--)

432.00M(4.42%)

392.00M(3.73%)

Other Merck Retained Products segment

--(--)

381.00M(3.90%)

462.00M(4.40%)

Keytruda

--(--)

309.00M(3.16%)

165.00M(1.57%)

Januvia/Janumet

--(--)

113.00M(1.16%)

91.00M(0.87%)

Simponi

--(--)

92.00M(0.94%)

94.00M(0.90%)

Zostavax

--(--)

76.00M(0.78%)

31.00M(0.30%)

Gardasi/Gardasil

--(--)

63.00M(0.64%)

5.00M(0.05%)

Varivax

--(--)

19.00M(0.19%)

61.00M(0.58%)

지역별

수익

비율

연간

연간

분기별

Europe and Canada

United States

Latin America, Middle East, Russia and Africa

Asia Pacific and Japan

China

Other

Europe, Middle East and Africa

Japan

Other Asia Pacific

Latin America

Canada

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

Europe and Canada

1.62B(26.03%)

1.76B(27.53%)

1.67B(26.71%)

1.63B(26.42%)

1.74B(27.62%)

1.73B(26.42%)

1.89B(24.34%)

--(--)

United States

1.60B(25.80%)

1.57B(24.55%)

1.48B(23.60%)

1.44B(23.28%)

1.38B(21.94%)

1.41B(21.56%)

2.02B(25.99%)

2.00B(20.41%)

2.46B(23.47%)

Latin America, Middle East, Russia and Africa

1.07B(17.25%)

1.03B(16.15%)

965.00M(15.41%)

895.00M(14.50%)

841.00M(13.34%)

857.00M(13.12%)

923.00M(11.87%)

--(--)

Asia Pacific and Japan

1.00B(16.09%)

1.05B(16.40%)

1.13B(18.03%)

1.14B(18.51%)

1.17B(18.61%)

1.53B(23.50%)

1.79B(23.00%)

--(--)

China

829.00M(13.34%)

847.00M(13.23%)

864.00M(13.80%)

917.00M(14.85%)

933.00M(14.80%)

873.00M(13.36%)

1.03B(13.21%)

908.00M(9.29%)

830.00M(7.90%)

Other

93.00M(1.50%)

137.00M(2.14%)

154.00M(2.46%)

151.00M(2.45%)

233.00M(3.70%)

133.00M(2.04%)

124.00M(1.59%)

-39.00M(-0.40%)

63.00M(0.60%)

Europe, Middle East and Africa

--(--)

3.74B(38.23%)

3.90B(37.11%)

Japan

--(--)

1.12B(11.46%)

1.17B(11.14%)

Other Asia Pacific

--(--)

943.00M(9.65%)

966.00M(9.20%)

Latin America

--(--)

937.00M(9.58%)

915.00M(8.71%)

Canada

--(--)

175.00M(1.79%)

195.00M(1.86%)